Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 μg g-1 ointment and calcipotriol 50 μg g-1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas

被引:59
|
作者
Ortonne, JP
Humbert, P
Nicolas, JF
Tsankov, N
Tonev, SD
Janin, A
Czernielewski, J
Lahfa, M
Dubertret, L
机构
[1] Hop St Louis, F-75010 Paris, France
[2] Hop Archet 2, Nice, France
[3] CHU St Jacques, Besancon, France
[4] Hop Lyon Sud, Pierre Benite, France
[5] Alexanders Univ Hosp, Sofia, Bulgaria
[6] Mil Med Acad, Sofia, Bulgaria
[7] Galderma, Dept Res & Dev, Sophia Antipolis, France
关键词
calcipotriol; calcitriol; chronic plaque psoriasis; sensitive skin areas; vitamin D;
D O I
10.1046/j.1365-2133.2003.05228.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Psoriasis involving sensitive skin areas remains difficult to treat because of the side-effects of topical corticosteroids and the irritancy potential of vitamin D-3 derivatives. Several clinical trials have demonstrated that calcitriol, the naturally occurring and hormonally active form of vitamin D-3 , is effective and safe at the dose of 3 mug g(-1) for the treatment of psoriasis affecting the trunk and limbs. Methods We compared the safety and efficacy of calcitriol 3 mug g(-1) ointment and calcipotriol 50 mug g(-1) ointment in a multicentre, randomized, investigator-blinded, left-right comparison in mild to moderate chronic plaque psoriasis affecting sensitive areas, defined as being the face, hairline, retroauricular and flexural areas. One pair of symmetrical and bilateral target lesions was selected from each area and assessed for perilesional erythema, oedema, and stinging/burning. Global assessment of local tolerability and global improvement were rated by the investigator, and the subjects were asked to evaluate the tolerability and efficacy of each product and to express their global preference. Results In the 75 subjects, calcitriol and calcipotriol both led to clearing of at least one target lesion in 21 (28%) of the subjects each. Perilesional erythema (P<0.001), perilesional oedema (P<0.02) and stinging/burning (P<0.001) were all significantly less severe with calcitriol than with calcipotriol. The subjects' evaluation of local tolerability was significantly (P<0.0001) in favour of calcitriol. Ten treatment-related dermatological events occurred in eight subjects, including one subject who experienced skin discomfort on both sides. All other events occurred only on the calcipotriol-treated side (irritant dermatitis, six subjects; contact dermatitis, one subject). Global assessment of improvement from baseline by the investigators was significantly greater for the calcitriol-treated lesions (P<0.02). The subjects' global preference was significantly in favour of calcitriol (P<0.02). Conclusions In the present study, calcitriol ointment was found to be better tolerated and would appear to be more effective than calcipotriol ointment in the treatment of psoriasis in sensitive areas.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 16 条
  • [11] High-concentration (20 μg g-1) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial
    Choi, J. W.
    Choi, J-W.
    Kwon, I-H.
    Youn, J-I.
    BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (06) : 1359 - 1364
  • [12] A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 mu g/g) and calcipotriol (50 mu g/g) in the treatment of chronic plaque psoriasis vulgaris
    Bourke, JF
    Iqbal, SJ
    Hutchinson, PE
    ACTA DERMATO-VENEREOLOGICA, 1997, 77 (03) : 228 - 230
  • [13] An Open-label, Multicenter Study of the Efficacy and Safety of a Weekday/Weekend Treatment Regimen With Calcitriol Ointment 3 μg/g and Clobetasol Propionate Spray 0.05% in the Management of Plaque Psoriasis
    Hudson, Charles P.
    Kempers, Steven
    Menter, Alan
    Papp, Kim
    Smith, Stacy
    Sofen, Howard
    Colon, Luz E.
    Johnson, Lori A.
    Gottschalk, Ronald
    CUTIS, 2011, 88 (04): : 201 - 207
  • [14] An Open-Label, Multicenter Study of the Efficacy and Safety of an AM/PM Treatment Regimen With Clobetasol Propionate Spray 0.05% and Calcitriol Ointment 3 μg/g in the Management of Plaque Psoriasis
    Menter, Alan
    Sofen, Howard
    Smith, Stacy
    Papp, Kim
    Kempers, Steven
    Hudson, Charles P.
    Colon, Luz E.
    Johnson, Lori A.
    Gottschalk, Ronald
    CUTIS, 2011, 88 (01): : 46 - 51
  • [15] Comparative efficacy of a two-compound ointment containing calcipotriol 50ig/G and betamethasone 0.5 μg/g (As dipropionate) after 1, 2, and 4 weeks of treatment of mild, moderate, and severe psoriasis
    Menter, A.
    Ganslandt, C.
    EADV: PROCEEDINGS OF THE 15TH CONGRESS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, : 715 - +
  • [16] A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of a Sequential Treatment Regimen of Clobetasol Propionate 0.05% Spray Followed by Calcitriol 3 mg/g Ointment in the Management of Plaque Psoriasis
    Brodell, Robert T.
    Bruce, Suzanne
    Hudson, Charles P.
    Weiss, Jonathan S.
    Colon, Luz E.
    Johnson, Lori A.
    Gottschalk, Ronald W.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (02) : 158 - 164